NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

The 248 PFS event — Phase Iii primary endpoint — occurred sometime late 2016. They just didn’t do the statistical analysis.

The 233 OS secondary endpoint passed sometime last summer. They planned to do the analysis on that until after the study ends.

They are opting to let additional progression free survival events and overall survival events accumulate, from the 331 patients enrollment, as the trial heads towards data lock completion. It is my long-standing view they plan to conduct the primary, secondary and tertiary endpoints once all 331 patients complete their study consents.